Featured CME Programs

Resize Text

Upcoming CME Events

  • ARHM 2022 Logo
    Atlantic Regional Hematopathology Meeting Future Directions of Hematopathology

    Advances in hematopathology, as well as in molecular and genetic information, are evolving at a rapid rate. However, it is difficult to remain current with the latest advances, let alone interpret their meaning and applicability to diagnosis and therapy. This meeting will focus on the “Future Directions of Hematopathology” with emphasis on the role of molecular pathology and new technologies in the diagnosis, prognostic stratification and treatment of challenging cases. Participants will be asked to incorporate advances in molecular and genetic information indicators/markers and test results in order to enhance interpretation of complex cases.

    Complimentary registration for all participants; includes breakfast, lunch, coffee breaks and program

    CME Registration Deadline: Wednesday, May 17, 2023

    Register

    Details

    Saturday, May 20, 2023
    8:30AM–3:00 pm EST Exhibit Hall Open

    Fox Chase Cancer Center Auditorium
    333 Cottman Avenue
    Philadelphia, PA 19111

    View Event Flyer

    Intended Audience

    Hematopathologists, pathologists of other subspecialties, hematologists/oncologists, radiation oncologists, internists, primary care providers, fellows and residents of pathology, oncology and other specialties

    Inquiries

    Lucía Tono, PhD, MEd: 215-728-3797
    Lucia.Tono-Ramirez@tuhs.temple.edu

    Presenters

    Keynote Speakers

    Jeffrey Medeiros, MD
    Professor & Chairman, Department of Hematopathology, MD Anderson Cancer Center

    Mariusz Wasik, MD
    Professor & Chair of Pathology; Associate Director of Cancer Center; DE&S Morel, S&S Bayster Chair in Molecular Diagnosis, Fox Chase Cancer Center

    Program Director

    Reza Nejati, MD
    Associate Professor; Director, Flow Cytometry Lab; Medical Director of TUH-FCCC Clinical Laboratories; Department of Pathology, Fox Chase Cancer Center

    Planning Committee Members

    Mariusz Wasik, MD
    Professor & Chair of Pathology; Associate Director of Cancer Center; DE&S Morel, S&S Bayster Chair in Molecular Diagnosis, Fox Chase Cancer Centery

    Nicholas Mackrides, MD
    Assistant Professor, Department of Pathology, Fox Chase Cancer Center

    Tahseen I. Al-Saleem, MD
    Professor Emeritus, Department of Pathology, Fox Chase Cancer Center

    Henry C. Fung, MD, FACP, FRCPE
    Vice-Chair, Department of Hematology/Oncology; Chief, Section of Hematologic Malignancies; Director, Fox Chase – Temple University Hospital; BMT Program, Fox Chase Cancer Center

    Submission of Abstracts

    We invite you to submit abstracts of clinical, scientific, and educational value with a focus on the role of molecular pathology and new technologies in the diagnosis, prognostic stratification and treatment of challenging cases.

    To submit an abstract for consideration, please send the following by Monday, April 3, 2023 to Lucia.Tono-Ramirez@tuhs.temple.edu:

    1. 1-page abstract, case description and diagnosis in a Word document (NO SLIDES)
    2. In the abstract, please specify the name, credential, affiliation and email of the person presenting the case if selected for oral presentation

    Notification of cases selected will be via email.

    If you are selected for ORAL PRESENTATION, please follow these instructions:

    • Presentations consist of a 15-minute lecture
    • You will receive an email from "eeds" (the CME software) requesting you to upload the following by Monday, May 8, 2023:
      1. Set of PowerPoint slides with a brief patient history and a couple of pictures to post on the eeds site prior to the event for reference—please abstain from providing a diagnosis or any discussion. Please title your slides as follow: “Presenter’s last name, first initial-WITH DIAGNOSIS-Title”
      2. Electronic copy of your PowerPoint slides as you will present them. Please title your slides as follow: “Presenter’s last name, first initial-WITH DIAGNOSIS-Title”
      3. Speaker disclosure of the person presenting the case

    If you are selected for POSTER EXHIBIT, please follow these instructions:

    • Poster exhibits will be displayed all day and can be presented during breaks.
    • Please bring a hard copy of your poster on the day of the event
      • 4'x6' poster boards with stands will be available

    Learning Objectives

    After attending this program, participants should be able to:

    At the end of this activity, participants should be able to:

    • Recognize the indicators/markers and test results to look for in complex cases to aid in diagnosis
    • When appropriate, incorporate recent molecular immunophenotypic and genetic information when interpreting results, determining diagnoses and selecting therapies
    • Discuss the latest advances related to the characteristics of progression in B-cell lymphomas

    Accreditation Statement

    The Temple Health Office for Continuing Medical Education is accredited by the Pennsylvania Medical Society to provide continuing medical education for physicians.

    Certification Statement

    The Temple Health Office for Continuing Medical Education designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should only claim the credit commensurate with the extent of their participation in the educational activity

  • 2022 SABCS
    21st Annual Highlights of the 2022 San Antonio Breast Cancer Symposium

    Presented by Fox Chase Cancer Center and the Temple Health Office for Continuing Medical Education, this virtual CME is designed to help medical, radiation, and surgical oncologists, gynecologists, radiologists, and primary care physicians translate the data from key presentations from the 2022 San Antonio Breast Cancer Symposium into practice.

    Join speakers from Fox Chase and Penn Medicine’s Abramson Cancer Center as they present information on the treatment of breast cancer, including screening, prevention, local control, chemotherapy, hormonal therapy, and advances in breast cancer biologic and their impact on breast cancer management.

    Register

    Details

    VIRTUAL CME: Thursday, January 19, 2023
    5:00–9:00 pm EST Exhibit Hall Open
    6:00–8:30 pm EST Education Program
    8:30–9:00 pm EST Virtual Q&A Reception & Exhibit Hall

    View Event Flyer

    Inquiries

    Lucía Tono, PhD, MEd: 215-728-3797
    Lucia.Tono-Ramirez@tuhs.temple.edu

    Presenters

    Program Director

    Lori J. Goldstein, MD, FASCO
    Professor Emerita, Department of Hematology/Oncology, Fox Chase Cancer Center

    Fox Chase Cancer Center Faculty

    Richard J. Bleicher, MD, FACS
    Professor, Department of Surgical Oncology; Leader, Breast Cancer Program; Director, Breast Fellowship Program

    Melissa McShane, MD
    Assistant Professor, Department of Hematology/Oncology; Associate Program Director, Hematology/Oncology Fellowship Training Program

    Saba Shaikh, MD
    Assistant Professor, Department of Hematology/Oncology

    Penn Medicine's Abramson Cancer Center Faculty

    Susan M. Domchek, MD
    Executive Director, Basser Center for BRCA; Director, MacDonald Cancer Risk Evaluation Center; Basser Professor in Oncology

    Angela DeMichele, MD, MSCE
    Jill & Alan Miller Endowed Chair in Breast Cancer Excellence; Professor of Medicine; Co-Leader, Breast Cancer Program; Co-Director, 2-PREVENT Translational Center of Excellence

    Learning Objectives

    After attending this program, participants should be able to:

    • Analyze the advances in the management of breast cancer and premalignant breast disease and, when clinically relevant, integrate new findings into the management of patients with breast cancer and premalignant breast disease.
    • When clinically relevant, apply new strategies for optimizing existing treatments into the management of these patients.
    • Analyze new developments in breast cancer research and current available clinical trials and, when clinically relevant, include this information in discussions with patients.

    Intended Audience

    The program is designed for medical, radiation, and surgical oncologists, gynecologists, radiologists, and primary care physicians. Other physician specialties, nurses, advanced practice clinicians, and healthcare professionals involved in the treatment of patients with breast cancer may find the program beneficial.

    Accreditation Statement

    The Temple Health Office for Continuing Medical Education is accredited by the Pennsylvania Medical Society to provide continuing medical education for physicians.

    Designation Statement

    The Temple Health Office for Continuing Medical Education designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should only claim the credit commensurate with the extent of their participation in the educational activity

  • On-Demand 20th Annual Highlights of the 2021 San Antonio Breast Cancer Symposium

    Presented by Fox Chase Cancer Center and the Temple Health Office for Continuing Medical Education, these enduring materials are designed to help clinicians translate the data from key presentations from the 2021 San Antonio Breast Cancer Symposium into practice.

    View speakers from Fox Chase and Penn Medicine’s Abramson Cancer Center as they present information on the treatment of breast cancer, including screening, prevention, local control, chemotherapy, hormonal therapy, and advances in breast cancer biologics and their impact on breast cancer management.

    Access-On Demand

     ... Expand

Disclosure Policy

It is the policy of the Temple Health Office for Continuing Medical Education to ensure that all sponsored continuing medical education activities are independently designed and produced and include content that is valid, objective, balanced, free of commercial bias and in the best interest to the public. Temple Health policy requires everyone in a position to control the content of an educational activity to disclose all financial relationships with ineligible companies and to disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentation(s). The Temple Health Office for Continuing Medical Education has established policies in place that will identify and resolve all conflicts of interest prior to this educational activity. Detailed disclosure will be made prior to the activity.